APEC1621E: NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF SELUMETINIB (AZD6244 HYDROGEN SULFATE) IN PATIENTS WITH TUMORS HARBORING ACTIVATING MAPK PATHWAY MUTATIONS
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
